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10th Meeting of the Irish Society 
of Human Genetics, Monday 24th 
September 2007. 
Postgraduate Centre, Belfast City Hospital, Belfast.
PROGRAMME:
10.00 – 11.00  Registration / Tea and coffee
11.00 – 11.01  Welcome
11.01 – 12.00  Spoken presentations Plenary I
12.00 – 13.00  Keynote address: “Sweet dreams: using 
genome wide association methods to find genes 
for diabetes and obesity” Mark McCarthy, 
University of Oxford 
13.00 – 14.00  Lunch + poster viewing
14.00 – 15.30  Spoken presentations Plenary II
15.30 – 16.00  Tea / coffee & poster viewing
16.00 – 16.15  Business meeting
16.15 – 17.15  Plenary address: “Genomic Approaches to 
Brain Diseases”.  
  Guy Rouleau, McGill University     
17.15 – 18.00  Wine Reception / Presentations / meeting close
SPOKEN PAPERS: 
S1. A prospective study of referrals from the Irish Traveller 
community  to  the  National  Centre  for  Inherited  Metabolic 
Disorders
AM  Murphy,  C  Halling,  SA  Lynch, AA  Monavari,  S  Harty,  E 
Crushell, EP Treacy.
The National Centre for Inherited Metabolic Disorders (NCIMD) and National 
Centre for Medical Genetics (NCMG), Dublin.
Irish Travellers  are  a  nomadic  people  in  whom  early  marriage, 
frequent child bearing and consanguinity are cultural norms. They 
number 22,445, <0.5% of the Irish population, 9.6% of the 1465 
patients  listed  at  NCIMD  on  January  1st  2007  were Travellers. 
To  date  21  different  inherited  metabolic  disorders  (IMDs)  are 
reported. Our aim was to prospectively survey all referrals from 
this community .The study is part of a larger ongoing project to 
compile a database of “Irish Traveller” genetic disorders to ensure 
appropriate planning of services and provision of care.
All referrals between January 1st and June 30th 2007 were reviewed, 
those  with  a Traveller  background  identified  and  the  following 
information sought; source, reason & age of referral, diagnosis & 
outcome.
Twenty eight (age range 1 day-16 yrs) of the 84 (33%) patients 
referred  were  Travellers.  15  new  diagnoses  of  IMDs  were 
established; of which 3 were genetic disorders not previously noted 
in this population (MSUD, X linked ALD and Hyperinsulinism). 
Six  patients  were  diagnosed  because  of  a  family  member  with 
an  IMD.  Eight  are  under  investigation  for  suspected  metabolic 
disorder (mitochondrial). The remaining five are thought to have 
an  undiagnosed  autosomal  recessive  disorder  because  of  the 
presence  of  multiple  affected  siblings.  Apart  from  the  patient 
with mucolipidosis, appropriate treatment was commenced once 
diagnosis was established with a good outcome to date.
This  study  highlights  the  huge  disease  burden  imposed  by  the 
increased  frequency  of  genetic  disorders  in  consanguinous 
communities and provides useful epidemiological information for 
service planning for patients with IMDs with particular reference to 
the Irish Traveller community
S2.  Counselling  issues  in  a  family  with  a  presumed  non-
pathogenic mutation in TSC2.
Crawford H, McKee SA. 
The Northern Ireland Tuberous Sclerosis Clinic, Northern Ireland Regional 
Genetics Centre, Belfast Health and Social Care Trust, A Floor, Belfast City 
Hospital, Lisburn Road, Belfast BT9 7AB
A diagnosis of Tuberous Sclerosis (TSC) can impact significantly 
on both the individual and the family. We report a family where the 
clinical presentation and genetic findings have presented difficulties 
in  approaching  management.  Case  1  is  an  8  year-old  boy,  who 
presented at age 8 with mild angiofibromata, but with no history of 
seizures or learning difficulty. MRI brain scan reported subcortical 
and periventricular hamartomas, and a small shagreen patch was 
found on clinical examination. He therefore fulfilled the diagnostic 
criteria for TSC. Mutation analysis identified a missense change in 
TSC2 – R261W – which was also found in the child’s mother. No 
other mutations were found, and the mutation is felt to be a rare 
non-pathogenic variant.
S3. Disorders of cholesterol biosynthesis in Ireland
J Chukwu, C Halling, ATaha, SA Lynch, AA Monavari, EP Treacy, 
AM Murphy. 
The  National  Centre  for  Inherited  Metabolic  Disorders  (NCIMD)  and 
The National Centre for Medical Genetics, OLCH, Crumlin Dublin 12. 
(NCMG)
Seven disorders of cholesterol biosynthesis are recognized of which 
Smith-Lemli- Opitz syndrome (SLOS) is the most common. These 
disorders are associated with major developmental malformations, 
unusual for metabolic diseases.
We reviewed the databases at the NCIMD and NCMG in order 
to identify all patients with inborn errors of cholesterol synthesis 
diagnosed in the 10 year period between June 1st 1997 and June 
1st 2007. Clinical features (congenital malformations, behavioural © The Ulster Medical Society, 2008.
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phenotype, growth and developmental profile), biochemical features 
(plasma sterol profile at diagnosis), genotype, ethnic background 
and treatment were noted.
Seven  patients  (age  range  3-45yrs)  attend  the  NCIMD  making 
cholesterol pathway defects the 13th most common condition treated 
here. An additional 6 deceased patients were identified from the 
database at the NCMGs. All patients had SLOS. None of the other 
6 disorders were identified.
The seven patients are being treated with cholesterol supplementation 
in  the  form  of  a  powder  or  egg  yolk. The  dose  of  cholesterol 
supplementation is titrated by monitoring growth, cholesterol and 
7  dehydro-cholesterol  levels  and  adjusting  levels  accordingly. 
There has been subjective improvement in general well-being and 
behaviour. Anecdotally parental perception is that supplementation 
has a huge beneficial effect. Cholesterol biosynthetic disorders are 
rare disorders in the Irish population but important to recognize as 
they are partially treatable.
S4. Enzyme Replacement Therapy in Northern Ireland
Fiona J Stewart. 
Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast 
BT9 7AB  Fiona.Stewart@belfasttrust.hscni.net
The  first  commercially  available  ERT  was  imiglucerase  for  the 
treatment of Gaucher disease.  This was available in Europe from 
1997.  Since then ERT has become available for Fabry disease, 
mucopolysaccharidosis type I (Hurler, Hurler-Scheie and Scheie), 
mucopolysaccharidosis type II (Hunter) and Pompe disease.  In 
Great  Britain  patients  travel  to  one  of  the  recognised  NSCAG 
centres to receive their ERT. Patients in Northern Ireland have been 
receiving ERT for nearly 5 years – some initially as part of clinical 
trials.








Fabry 8 8 / 0 7 / 1 Fortnightly
MPS I 4 1 / 3 1 / 3 Weekly
MPS II 2 1/1 2/0 Weekly
Pompe Due to start
In addition we have treated 4 children with MPS I (Hurler) with 
a finite course of ERT pre and post bone-marrow transplant. All 
patients have reported an improvement in their quality of life and 
clinical improvement has been confirmed by regular assessments 
and supporting data will be presented. Many of our patients are now 
on home infusions and this is working very well.
S5. Natural selection and disease susceptibility at the coagulation 
F13B locus 
Anthony  W  Ryan1,2,3,  David  Hughes1,  Thomas  Ryan2,  Ross 
McManus2 and Mark Stoneking1.  
1   Max Planck Institute for Evolutionary Anthropology, Deutscher Platz 
6, D-04103 Leipzig, Germany. 
2   Department of Clinical Medicine, Trinity College, Dublin and Institute 
of Molecular Medicine, Trinity Centre for Health Sciences, St James’s 
Hospital, Dublin 8, Ireland. 
3   E: aryan12@tcd.ie
High levels of inter-population differentiation at the coagulation 
F13B locus may be interpreted as evidence of localised natural 
selection.  However,  a  neutral  explanation  is  also  possible.  We 
re-sequenced 4.6kb of the gene, encompassing all exons, splice 
junctions and 1.4kb of the promoter in African, European and Asian 
samples. This revealed three major lineages, which correspond to 
the common protein alleles and differ from each other at a non-
synonymous substitution in exon 3 and a novel splice acceptor in 
intron K. There is evidence that these lineages are not functionally 
equivalent,  a  pre-requisite  for  the  action  of  natural  selection. 
Furthermore, our case-control analyses confirm that variability at 
this locus modifies susceptibility to myocardial infarct (OR = 1.88 
[1.18 – 2.99], P = 0.0047). When our sequence data were combined 
with additional sequences from the SeattleSNPs database, Fu and 
Li’s test for selection suggested a significant departure from neutral 
expectations  (D*  =  -2.92556,  P  =  0.02).  Patterns  of  extended 
haplotype homozygosity from HapMap populations also provide 
evidence of adaptation (P < 0.05). Thus, several independent lines 
of  evidence  suggest  that  the  F13B  locus  has  been  subjected  to 
localised natural selection during recent human evolution. Possible 
causes of this selection are discussed.
S6. An assessment of Ireland as a population for whole genome 
association studies
Colm  Ó’Dúshláine,  Ciara  Dolan,  Alice  Stanton,  David  Croke, 
Reetta  Kalviainen,  Samuel  Berkovic,  Terry  O’Brien,  Sanjay 
Sisodiya,  David  Goldstein,  Derek  Morris,  Norman  Delanty, 
Gianpiero Cavalleri. 
Trinity College Dublin, St James’ Hospital, Dublin 8.
The transferability of HapMap SNPs to different populations is 
a  significant  factor  determining  the  success  of  whole-genome 
association studies. We examined the extent to which the linkage 
disequilibrium of HapMap SNPs agreed with the same estimates 
for  these  SNPs  within  a  number  of  populations.  Comparisons 
were made for “test” populations of Caucasian individuals from 
Ireland, UK, Finland and Australia (4424 SNPs genotyped in 1178 
individuals,  covering  279  genes).  Higher  overall  concordance 
was  observed  between  HapMap  CEPH  individuals  and  Irish 
and UK populations (Spearman Rho 0.72, p<0.0005), the latter 
also exhibiting the highest level of similarity to each other from 
pairwise  comparisons  all  our  test  populations  (Spearman  Rho 
0.76, p<0.0005). Similar results were obtained when comparing 
haplotype diversity (Spearman Rho IRL=0.96, p<0.0005; UK=0.97, 
p<0.0005) and tag portability estimates (Spearman Rho IRL=0.55, 
p=0.0004; UK=0.58, p=0.0002). These findings have implications 
for researchers seeking to carry out fine mapping studies of disease 
susceptibility  loci,  particularly  when  these  loci  are  identified 
from studies where candidate SNPs are derived from a HapMap 
reference. Specifically, our data shows that certain populations are 
in better agreement with HapMap than others and thus are likely to 
have more power in identifying disease susceptibility loci.  
S7. The glutamatergic synapse protein HOMER2 is associated 
with schizophrenia in the Irish population
William  P.  Gilks1,  Emma  Allott1,  Gary  Donohoe1,  John  L. 
Waddington2, Michael Gill1, Aiden P. Corvin1, Derek W. Morris1  
1  Neuropsychiatric  Genetics  Research  Group,  IMM  and  Dept.  of 
Psychiatry, Trinity College Dublin, Ireland. 2Royal College of Surgeons 
in Ireland, Dublin, Ireland
Glutamatergic  synapse  dysfunction  has  been  implicated  in 
schizophrenia  pathogenesis.  To  identify  potential  susceptibility © The Ulster Medical Society, 2008.
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genes, we combined data from genome-wide linkage studies, the 
synaptic proteome and from keyword searches of genomic databases 
for glutamatergic genes. HOMER2 is located at chromosome 15q24, 
a  region  of  significant  linkage  to  schizophrenia. The  HOMER2 
protein forms a scaffold for post-synaptic glutamate receptors. To 
investigate  its  role  in  schizophrenia  we  selected  HapMap-based 
tagging SNPs, integrating our own novel HapMap genotype data 
on five predicted functional SNPs into the SNP selection algorithm. 
We genotyped 12 tagging SNPs in our Irish sample of 375 cases and 
812 controls. Single-marker association analysis showed disease 
association  at  rs869498,  rs7174726  and  rs12913501  (each  SNP 
p<0.05, OR>1.3). These three SNPs are located in a 25kb region 
of intron 1 of the gene but are not in high linkage disequilibrium 
with  each  other  (r2=0.02). There  was  significant  association  of 
all two-marker haplotypes of the three SNPs, notably rs7174726-
rs12913501 (p<0.0005). This 25kb region covers 4kb unique to 
higher primates strongly predicted to contain a transcription factor 
binding-site. HOMER2 is developmentally regulated, controlling 
synaptic  plasticity  and  calcium  homeostasis.  This  information, 
combined  with  our  association  results  identifies  HOMER2  as  a 
putative susceptibility gene for schizophrenia.
S8. A linkage and association study of hip osteoarthritis.
D McGibbon, C Benson, G Meenagh, G Wright, M Doherty, A 
Hughes. 
Queen’s University Belfast.
Genetic and environmental risk factors affect risk of osteoarthritis 
(OA). Our study aims to identify susceptibility genes for hip OA.
A total of 426 Northern Ireland hip OA patients were genotyped 
using microsatellite markers and  non-parametric linkage analysis   
carried  out  on  affected  sib-pairs.  A  peak  LOD  score  of  1.64 
(p=0.003)  at  25cM  on  chromosome  19  indicated  this  region  as 
potentially  harbouring  an  osteoarthritis  susceptibility  gene. The 
best candidate gene in this region was COL5A3, which is flanked 
by genes OLFM2 and RDH8. An association study using single 
nucleotide polymorphisms (SNPs) on unrelated Northern Ireland 
cases  confirmed  interest within this region  with a significant 
p-value for  SNP rs4804474 in OLFM2 (p=0.016). This result was 
reproduced in a separate collection of 280 hip OA cases collected in 
Nottingham (p=0.03). The Northern Ireland and Nottingham cases 
combined gave the most significant p value of 0.009 for rs4804474. 
SNP’s rs37455849(COL5A3) and rs889128(RDH8) give significant 
p-values in the Northern Ireland and Nottingham cases respectively 
of 0.037 and 0.025 but these values could not be reproduced. Further 
SNP genotyping across this region is required to fully elucidate the 
pattern of association and the location of the hip OA susceptibility 
gene.
S9. The Pathway to Breast Cancer Invasion.
Seona McErlean, Natalie Scott, Jenny Worthington, Gillian Brown, 
Adriana Falchi, Daniel Berrar, Anthony J Bjourson. 
Institute  of  Biomedical  Sciences,  University  of  Ulster,  Cromore  Road 
Coleraine. N. Ireland BT52 1SA. aj.Bjourson@ulster.ac.uk. 
Background:  Considering  the  fact  that  the  majority  of  breast 
cancer deaths are due to metastatic rather than the primary tumours, 
comparatively little consensus exists on the mechanisms of cancer 
invasion and spread to distant sites.  In an attempt to better understand 
the invasive and metastatic processes we developed a model of 
breast  cancer  invasion  and  metastasis  in  vitro  and  subsequently 
validated this in a mouse model.
Methods:  We  developed  a  minimalist  model  of  breast  cancer 
invasion  in  vitro  by  converting  a  well  known  weakly-invasive 
breast cancer cell line into a series of progressively hyper-invasive 
sub-clones,  ranging  from  non-invasive  –  to  highly  invasive.   To 
identify  the  master  regulators  of  invasion  we  performed  micro-
RNA (miRNA), messenger RNA (mRNA) transcriptional profiling 
and  selected  promoter  methylation  analyses  on  the  non-invasive 
parental and selected hyper-invasive sub-clones.  Systems biology 
pathway analyses was employed to identify genes that may represent 
key regulators of invasion. To validate the in vitro data, the parental 
(non-invasive) and hyper-invasive lines were stably transfected with 
a luciferase and their growth and metastatic spread was monitored in 
SCID mice using a Xenogen whole body imaging system.
Results:  The  pathway  to  invasion  was  clearly  associated  with 
an  epithelial-mesenchymal  transition  (EMT),  and  a  profound 
reduction in extracellular matrix (ECM) adhesion, altered cadherin 
expression, and silencing of interferon-γ (IFNγ) responsive genes 
consistent with archetypal immunoediting.  Significantly however, 
this  occurred  independent  of  any  Darwinian  immune  selective 
pressure and the simple process of selecting hyper-invasive cells 
concomitantly selected for a population that surprisingly, were also 
highly resistant to apoptosis (tolerant of hypoxia, more resistant 
to γ radiation, and more Trail-resistant).  In addition, whole body 
imaging demonstrated that the in vitro selected cells were extremely 
invasive in vivo in SCID mice and rapidly metastasised to multiple 
organs within 3-4 weeks.
Conclusion:  We have generated a useful model of invasion and 
metastasis.  The genes identified appear to be directly related to 
the primary cause, rather than the consequence of cancer invasion 
& metastasis and may find utility as novel biomarkers and novel 
targets for therapeutic intervention.
S10. Sexual antagonism and autism susceptibility in the Xq/Yq 
pseudoautosomal region (PAR2)
Andrew McLellan, Freda Wynne, Melanie Ball, Tom Moore. 
Department  of  Biochemistry,  Biosciences  Institute,  University  College 
Cork, College Road, Cork, Ireland.  E: t.moore@ucc.ie
Autism is a neurobehavioural disorder associated with impaired 
language  development,  poor  social  interactions  and  stereotyped 
repetitive behaviours. We hypothesised that deregulation of the Xq/
Yq pseudoautosomal region (PAR2) is involved in the profoundly 
male-biased affected sex ratio in autism. We therefore carried out 
TDT analysis on 95 autism multiplex families using 21 genetic 
markers in this region. In the proximal zone, which contains the 
brain-expressed imprinted SPRY3 and SYBL1 genes, we observed 
that multiple markers exhibited linkage / association with autism. In 
a further analysis involving datasets from which all male offspring or 
all female offspring were removed, we observed over-transmission 
of  ‘opposite’  marker  alleles  to  affected  males  and  females  for 
approximately half of the marker loci examined. We interpret these 
findings as evidence of sexually antagonistic selection operating at 
this locus. Our observations have general implications for human 
genetic studies and, more specifically, for the evolution and function 
of PAR2 genes.
POSTER PRESENTATIONS:
P1.  EuroGentest:  Quality  Management  and  accreditation  of 
genetic testing services© The Ulster Medical Society, 2008.
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David  E.  Barton1,  Ros  J.  Hastings2,  Sarah  Berwouts3,  Christine 
Brady1, Philippe Corbisier4, Anniek Corveleyn3, Rob Elles5, Brian 
Fowler6, David Gancberg4, Piotr Litynski6, Milan Macek Jr7, Ute 
Malburg8, Gert Matthijs3, Michael Morris9, Clemens Mueller8, Nick 
Nagels3, Bettina Quellhorst-Pawley2, Alexandra Stambergova7, Jan 
Vermeesch3, Kate Vickers5, Elisabeth Dequeker3.    
1  National Centre for Medical Genetics, Dublin, Ireland, 
2  John Radcliffe Hospital, Oxford, United Kingdom, 
3  KU Leuven, Leuven, Belgium, 
4  European Commission, Geel, Belgium, 
5  St. Mary’s Hospital, Manchester, United Kingdom, 
6  University Children’s Hospital, Basel, Switzerland, 
7  Charles University, Prague, Czech Republic, 
8  Universitaet Würzburg, Würzburg, Germany, 
9  CMU, Geneva, Switzerland.
The  EuroGentest  network  aims  to  improve  and  harmonize 
the  quality  of  genetic  services  in  Europe,  from  test 
development  through  to  information  for  patients.  The 
network  encompasses  Biochemical,  Clinical,  Cyto-  and 
Molecular  Genetics,  Genetic  Counselling  and  patient  groups.   
Since January 2005, the EuroGentest Quality Management group 
has  disseminated  information  on  accreditation  through  five 
international workshops. A database on the current status of QAu 
in European genetic testing services will soon be publicly available. 
On the EuroGentest website, laboratories can find the EQA scheme 
most appropriate to their needs through discipline specific registers 
of  schemes  in  Europe.  All  three  laboratory  disciplines  have 
expanded their repertoire of EQA including a pilot pan-European 
cytogenetics  scheme,  CEQA.  Minimum  quality  guidelines  have 
been published for cytogenetics and some biochemical analytes. 
Draft guidelines for microarrays will be published later this year. In 
collaboration with EMQN, best practice meetings will be organised 
in 2007 for Familial Breast Cancer, Spinocerebellar Ataxias and 
Maturity  Onset  Diabetes  of  the  Young  to  generate  consensus 
guidelines. Finally QCMs for Prader-Willi/Angelman syndromes 
are being developed and validation of MLPA, diagnostic CF-testing 
kits and DNA extraction methods are in progress through a core 
group of accredited laboratories with reports due this year.
P2.  Osteopetrosis:  clinical  and  skeletal  findings  in  2  early 
childhood cases.
Alex Magee1, Sally Ann Lynch2, Amaka Offiah3. 
1.   Regional Genetics Service, Belfast City Hospital. 
2.   National Centre for Medical Genetics, Our Lady’s Hospital, Dublin.  
3.   Department of Paediatric Radiology, Great Ormond Street Hospital.
Osteopetrosis is a rare, heterogeneous condition, characterised by 
osteoclast failure and classified into three forms: infantile malignant 
autosomal recessive osteopetrosis (ARO), intermediate autosomal 
recessive osteopetrosis (IRO) and autosomal dominant osteopetrosis 
(ADO). We present an unrelated 8 year-old girl and 5 year-old boy 
with a clinical and skeletal diagnosis of osteopetrosis and discuss 
the difficulties in determining recurrence risk in isolated cases.
Case 1.  Elder of 2 sibs; non-consanguineous, clinically normal 
parents.  Referred because of dental anomalies.  Noted to have 
macrocephaly, short stature and prominent upper tibiae.  No history 
of fractures. Skeletal survey showed findings consistent with IRO.   
No evidence of bone marrow compromise, abnormal renal function 
or cranial nerve compression.
Case 2. Youngest of 3 sibs; non-consanguineous, clinically normal 
parents.  Fractures of both tibiae following trivial injuries age 2y. 
Normal stature with frontal bossing. Skeletal survey suggested type 
1 ADO although IRO not out ruled.  No evidence of bone marrow 
compromise or abnormal renal function.
Mutations in the ClCN7, ATP6i and other genes have been identified, 
but not all genes determining OP are known.  In isolated cases of 
OP, diagnosis of type, and therefore recurrence risk, still relies on 
clinical and radiological findings. Some cases remain difficult to 
classify resulting in ambiguity over recurrence risks.
P3. The  Genetic  Basis  Of Autosomal  Recessive  Osteogenesis 
Imperfecta In The Irish Traveller Population
J Walsh1, D Lambert  1, DM Baldridge2, R Morello2, D Eyre3, B 
Lee2, AJ Green1,4  
1.   National Centre for Medical Genetics, Our Lady’s Hospital, Crumlin, 
Dublin, Ireland, 
2.   Department of Molecular and Human Genetics, Baylor College of 
Medicine, Houston, Texas. 
3.   Department of Orthopaedic Surgery, University of Washington, Seattle, 
Washington, and  School of Medicine and Medical Science, University 
College Dublin
Osteogenesis Imperfecta (OI) is usually an autosomal dominant 
disorder,  and  is  clinically  classified  according  to  the  Sillence 
classification of 1-IV . However, the Irish Traveller population has 
an autosomal recessive form of severe OI, which fits with type II/
III in the Sillence classification.  We have identified 16 patients 
in  5  extended Traveller  families,  where  almost  all  the  affected 
children are born with severe limb and thoracic deformities due 
to multiple fractures, including in utero fractures. Most have died 
within 6 months, of respiratory compromise. However, there are 
two surviving affected children at ages 5 years.
No type I collagen abnormality has been described in the Irish 
Traveller OI (Pope et al. 1989). Recently, the genetic basis of one 
form of autosomal recessive OI has been found, due to homozygous 
mutations  in  a  gene  CRTAP  or  cartilage  associated  protein 
(Morello et al. 2006). CRTAP is homologous to a family of prolyl 
3-hydroxylases  which  modify  collagen,  and  mutations  affected 
the modification of collagen fibrils.  A partner protein for CTRAP, 
LEPRE1 or prolyl 3-hydroxylase 1 (P3H1) has also found to be 
the basis of another autosomal recessive form of OI in people of 
African origin (Cabral et. al. 2007).  
Samples  from  3  affected  Irish Traveller  children  were  analysed 
for mutations in CRTAP and P3H1. No mutations were found in 
CTRAP, but all three were homozygous for a frameshift mutation 
c.232delC in exon 1 of the P3H1 gene. Cultured fibroblasts from 
one affected case were analysed by mass spectroscopy for prolyl 
3-hydroxylation of type I collagen. The level of hydroxylation was 
markedly reduced, at a level of 15%, compared to 95-98% seen in 
normal controls.
These findings have now identified the genetic basis for autosomal 
recessive OI in the Irish travellers. This will now lead to improved 
OI diagnosis and genetic counselling for Travellers who have a 
family history of severe or lethal OI.  In addition, these findings 
give further insights into the biology of bone collagen.
P4.  Investigation  of  the  impact  of  the  19bp  Deletion 
polymorphism in Intron 1 of Dihydrofolate Reductase (DHFR) 
on gene expression.© The Ulster Medical Society, 2008.
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Kirsty O’Brien,Anne Parle-McDermott. 
Nutritional  Genomics  Group,  School  of  Biotechnology,  Dublin  City 
University. 
Dihydrofolate reductase (DHFR) is an important folate metabolising 
enzyme that is essential to cellular proliferation because of its role 
in regenerating tetrahydrofolate (THF) from dihydrofolate (DHF), 
which is formed during the folate-linked synthesis of thymidine.   
Folate genes are considered candidates for association with neural 
tube defects (NTDs) such as spina bifida due to the preventative 
effect of periconceptional maternal supplementation with folic acid.   
Investigation of an intronic 19bp deletion polymorphism within the 
DHFR gene found a significant protective effect in mothers of NTD 
cases when present in one (Relative Risk 0.59 (95%CI: 0.39-0.89), 
p= 0.01) or two copies (Relative Risk 0.52 (95%CI: 0.32-0.86), 
p= 0.01).  Analysis of mRNA levels revealed a small increase in 
expression (~1.5 fold) associated with the 19bp intronic deletion 
polymorphism, but this was not significant (Parle-McDermott et 
al., Am J Med Genet 2007;143(11):1174-1180). 
We sought to further investigate the potential impact of the DHFR 
19bp  intronic  deletion  polymorphism  on  gene  expression  by 
employing a recombinant dual luciferase system.  PCR products 
representative of DHFR intron 1 with and without the 19bp deletion 
were cloned into a Gateway® compatible pGl3- promoter vector 
and verified by sequencing. Luciferase assays will be performed in 
HEK293 cells and the data presented. 
P5. Disease frequency of Inborn Errors of Metabolism in the 
Irish Traveller Community
AM Murphy. 
The  National  Centre  for  Inherited  Metabolic  Disorders  (NCIMD)  and 
National Centre for Medical Genetics (NCMG), Dublin
The  frequency  of  Inherited  Metabolic  Disorders  (IEMs)  varies 
between ethnic groups, reflecting founder effect, genetic isolation, 
and the potential effects of consanguinity. These disorders are a 
major cause of morbidity and mortality in “Irish Travellers“, an 
endogamous group of nomads who number 22,000 in Ireland and 
15.000 in the UK.
We aimed to compare the birth prevalence of IEMs in Traveller with 
non-Traveller children attending a tertiary level metabolic centre and to 
examine possible genetic factors contributing to observed differences. 
A  retrospective  review  of  diagnoses  in  Travellers  was  performed 
for 5 years (2002-2006). Mean birth prevalence was calculated and 
compared with overall figures for IEM’s in the total population.
Travellers constitute 9% of the total patient group, but only 0.5% 
of the Irish population. 21 IEMs were noted, Galactosaemia, MPS 
I, Mitochondrial cytopathies, Glutaric Aciduria Type I,GSD Type 
IIIa, Mucolipidosis Type II, Hyperprolinemia Type 11,progressive 
familial  intrahepatic  cholestasis  Type  I  (PFIC1)  and  carbonic 
anhydrase deficiency  being the commonest. The birth prevalence of 
IEMs in the Traveller group for this period was 12/1000. That for the 
total population was 2.45/1000. Common homozygous mutations in 
all cases of galactosemia (Q188R), MPS 1(W402X), GA1(E365K), 
Mucolipidosis type II (c.3502_3delCT), Hyperprolinemia Type II 
(G521fs(+1)) and PKU (R408W) confirm the homozygous nature 
of this ethnic group. 
We  propose  that  the  high  incidence  of  IEMs  in  Irish Travellers 
may  reflect  initial  founder  effects  and  the  increased  rate  of 
consanguinity. 
P6. Myoclonus Dystonia-  Phenotype- Genotype Correlation in 
the Irish Paediatric Population
Langseth A1, Doherty E1, Nestor T  1, Lynch T2, Asmus F3, Mary 
MD1   
1.  Department of Neurology, The Children’s University Hospital Temple 
Street. 
2.   Department of Neurology, The Mater Hospital Dublin 1. 
3.  Department of Genetics, Teubingen, Germany
Myoclonus dystonia (DYT 11) is characterised by proximal myoclonic 
jerks and dystonia which causes torticollis and writers cramp.  It 
has been associated with mutations on the epsilon sarcoglycan gene 
on chromosome 7q21 and may be alcohol responsive.  An audit of 
over 70 patients seen at a quaternary paediatric movement disorder 
clinic revealed 21 patients with myoclonus dystonia.
Aim:  to investigate clinical phenotype genotype correlation in Irish 
children with myoclonus dystonia. 
Methods: 21 children in 17 M-D families were evaluated using a 
standardized neurological examination and review of video material.   
SGCE mutation analysis was performed on all patients.
Results: Age of onset ranged from 18 months to 14 years.  A 
positive family history was seen in 11/21.  Presenting symptoms 
were hand tremor, paroxysmal gait abnormality writing difficulties 
or a combination thereof.  Clinical evaluation with pectoral muscles 
exposed showed irregular myoclonic jerks in all patients.  SGCE 
mutation was found in 7/21 patients.  All patients who had taken 
alcohol were alcohol responsive.  
Conclusion: A typical adult M-D phenotype was rarely seen in 
children.  Children  were  more  likely  to  present  with  lower  limb 
symptoms.  Children with a positive mutation were more likely to 
present at an earlier age, were more likely to have a positive family 
history and were more likely to have lower limb symptoms.
P7. The IKBL protein inhibits TLR mediated activation of gene 
expression by NF kappa B
Arun Kumar Mankan, Jacqueline Daly, Emma Caraher, Dermot 
Kelleher, Ross McManus.
Department of Clinical Medicine, Trinity College Dublin and Institute of 
Molecular Medicine, Dublin Molecular Medicine Centre, Trinity Centre for 
Health Sciences, Trinity College Dublin, Dublin, Ireland, 8.
The Inhibitor of NF Kappa B like (IKBL/NFkBIL1) gene encodes 
a  protein  homologous  to  members  of  the  IKB  family.  IKBL  is 
situated in the MHC and a number of different polymorphisms in 
the gene have been associated with diseases such as Myocardial 
Infarction, Rheumatoid Arthritis, Diabetes Mellitus, Celiac Disease 
and Crohns Disease.
The function of IKBL protein has not yet been reported. We have 
demonstrated, by both EMSA and Luciferase Assays, that over-
expression of IKBL inhibits the activity of NF kappa B. 
We  have  further  demonstrated  that  IKBL  inhibits  NF  kappa  B 
activation by both TLR 2 and TLR 4 pathways. mRNA and protein 
expression  of  IL8,  a  NF  kappa  B  regulated  pro-inflammatory 
cytokine, was also inhibited by IKBL. 
We show that IKBL and HDAC3 may co-localise in the nucleus 
offering a possible mechanism since HDAC3 is a known regulator 
of transcription factors.© The Ulster Medical Society, 2008.
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Our study suggests that IKBL is a member of the novel inhibitors of 
NF kappa B such as MAIL that are located in the nucleus and may 
inhibit the activity of NF kappa B by regulating the activity of other 
proteins that bind to NF kappa B within the nucleus.
P8. Use of the Promega Powerplex® 16 kit to exclude maternal 
cell contamination in prenatal testing
Brónagh Ó hIcí, Edith Gould, David E. Barton. National Centre for 
Medical Genetics, Our Lady’s Children’s Hospital, Crumlin, Dublin 
12. E: bronagh.ohici@olhsc.ie
The exclusion of maternal cell contamination of prenatal samples is 
an important step in prenatal molecular genetic testing particularly 
when the prenatal sample shows the same genotype in the diagnostic 
test as the maternal sample.  Traditionally, the exclusion of maternal 
cell contamination has been carried out by typing a number of 
linked  or  unlinked  microsatellite  markers  from  the  maternal, 
paternal and foetal samples.  This work becomes challenging when 
the microsatellite markers used are uninformative.  If this occurs 
with several of the microsatellite markers selected for analysis the 
reporting of results may be delayed, as further microsatellite markers 
must be typed to complete the analysis.  To assist in eliminating 
some of these problems, and with the additional aim of reducing the 
reporting time, we have been investigating the use of a commercial 
kit called Powerplex® 16 (Promega) for the exclusion of maternal 
cell contamination.  This kit co-amplifies, in a single PCR reaction, 
15 highly-informative microsatellite markers and the amelogenin 
locus.  Here we describe the sensitivity of the Powerplex® 16 kit 
in detecting maternal cell contamination as low as 5% in prenatal 
samples.
P9. A systems approach to datamining association signals from 
whole-genome association studies
Colm  Ó’Dúshláine,  Derek  Morris,  Elaine  Kenny,  Carlos  Pinto, 
Michael Gill, Aiden Corvin.
Trinity College Dublin, St James’ Hospital, Dublin 8.
Whole-Genome Association (WGA) studies have the potential and 
power to detect a large number of significant associations with a 
disease phenotype. Understanding these findings can be difficult 
and replication is often an integral part of this type of study, but 
even this may only identify low hanging fruit. Published WGA 
data shows that, while novel genes have been found for the various 
phenotypes, a large number of genes still remain to be identified. 
For example, in a study of type 2 diabetes that found 5 genes for 
the  disorder,  Saxena  et  al  (2007)  commented  that  these  5  loci 
contribute only modestly to the overall variance in diabetes risk 
(~2.3%),  indicating  that  many  more  genes  remain  to  be  found. 
We present a systems biology approach to mining WGA data. By 
availing of gene interaction data from KEGG HPRD BIND and 
Reactome, we integrate genes containing significantly associated 
SNPs into gene interaction networks. This provides a platform for 
inferring biological pathways enriched for disease associated genes. 
Our approach is flexible, taking account of the available interaction 
data  and  the  number  of  significantly  associated  genes  under 
investigation, and permits varying levels of intermediate interacting 
genes between the associated genes. We apply this method to the 
investigation of a number of existing WGA studies, highlighting 
heretofore unobserved pathway signals.
P10. Development of a C.elegans model system for genetic and 
molecular  dissection  of  epigenetic  mechanisms  underlying 
trinucleotide expansion disorders.
Katherine Schouest1, Avril Coghlan2, Charles Spillane1. 
1.   Dept Biochemistry & Biosciences Institute, University College Cork, 
Cork, Ireland. www.ucc.ie/spillane 
2.  Wellcome Trust Sanger Institute, Cambridge, U.K.
Model organisms are essential for the rapid advancement of genetic 
research on human diseases. C. elegans has already proven to be 
a powerful biomedical model in dissecting principles underlying 
diseases  like  Huntington’s  Disease  and  Myotonic  Dystrophy,  as 
well as in revealing potential targets for therapeutic treatment. We 
are using C. elegans as a model organism to investigate epigenetic 
phenomena  associated  with  nucleotide  repeat  disorders  and  to 
identify modifiers that regulate the size and rate of the expansions. 
To identify candidate tester loci for our research we have screened 
the C. elegans genome for trinucleotide repeats that have at least 
12 trinucleotide repeats and a high level of purity, as these are most 
likely  to  undergo  expansion  or  contraction.  We  have  identified 
20  such  repeats  located  in  C.  elegans  exons  and  17  repeats 
located within introns. To select one or more variable repeats for 
further analysis, the extent of polymorphism of these repeats is 
currently being examined over 48 wild isolates of C. elegans. The 
identification of polymorphic repeat loci will allow monitoring of 
these alleles through multiple generations in control animals and 
animals depleted of candidate epigenetic modifiers via RNAi. The 
project will ultimately facilitate the understanding of the epigenetic 
phenomena causing nucleotide expansion disorders.
P11. Analysis of SOD1 gene for IVS 2+50 del 7 genomic deletion 
in Northern Irish Keratoconus Patients
Dash DP1, S George3, Silvestri G1,3, J Jackson3, D Frazer3, Hughes 
AE2, Willoughby C1,3,
Centre  for Vision  Sciences1,  Medical  Genetics  2,  Queen’s  University  & 
Royal Victoria Hospital3, Belfast, N. Ireland.
Purpose: Oxidative stress has been suspected as a major contributor 
to pathogenesis of keratoconus (KC) as accumulation of cytotoxic 
by-products  from  nitric  oxide  and  lipid  peroxidation,  abnormal 
antioxidant enzymes found in KC cornea. Recently a heterozygous 
7bp deletion in intron 2 (IVS 2+50 del 7) close to the 5’ splice 
junction of the super oxide dismutase 1 (SOD1, MIM:147450) gene 
was reported in three KC patients (Udar et al., IOVS; 2006). The 
purpose of this study was to screen for the IVS 2+50 del 7 of SOD1 
gene in KC patients from Northern Ireland.
Methods:  Blood  samples  were  collected  from  17  KC  patients 
at  RVH  Eye  Clinic  and  DNA  was  extracted  from  leucocytes. 
Conventional  and  FAM-labelled  oligonucleotide  primers  were 
designed flanking the genomic deletion, IVS 2+50 del 7 of SOD1 
gene. Screening for the intronic deletion was performed by PCR 
based direct cycle sequencing and fragment length analysis using 
ABI 3100 automated DNA sequencer. 
Results:  Seven  out  of  17  sporadic  KC  patients  appeared  to 
show a 2-3 bp genomic deletion within the previously published 
intronic region when sequencing in one direction, but there was no 
frameshift in the downstream sequence. Sequencing in the reverse 
direction and fragment length analysis failed to demonstrate any 
intronic deletion. 
Conclusions: The genomic deletion (IVS 2+50 del 7) of SOD1 gene 
was not found in a subset of the NI population with KC. Sequencing 
results in this region should be interpreted with caution. Patient 
recruitment is ongoing and further analysis of the entire coding 
region of SOD1 is required to elucidate the role of this anti-oxidant © The Ulster Medical Society, 2008.
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enzyme  in  KC.    [Funding Authority:  Research  &  Development 
Office, Northern Ireland].
P12. Predictive Testing for Carney Complex in a Child
Deirdre Donnelly, Shane McKee. 
Department of Clinical Genetics, Belfast City Hospital, Belfast
This is a case of a 4 year old girl with a three-generation family 
history  of  Carney  Complex.    Carney  Complex  is  an  autosomal 
dominant condition, with around 400 patients reported worldwide.   
The phenotype is variable and there may be a degree of under-
diagnosis.    Manifestations  include  skin  pigment  abnormalities, 
myxomas,  endocrine  tumours  and  schwannomas.    The  family 
mutation has been found, delta FSC18 PRKAR1A.  All affected 
family members have characteristic facial freckling.  The child had 
a milder distribution of facial freckles and was considered to be 
affected by the family.  Her mother requested predictive testing 
for  confirmation.    No  intervention  is  recommended  routinely 
until puberty in Carney Complex, although cardiac myxomas may 
present at any time from birth.  These can cause embolic events or 
obstruct blood flow, leading to sudden death.  Our case raises the 
question of whether to test an asymptomatic child who has similar 
facial features as affected family members.  In this situation, the 
child may consider themselves affected.  This child tested positive 
for the family mutation.  Her mother was brought back to the clinic 
alone to be informed.  The child has been referred to a paediatric 
cardiologist.  She will be offered a genetics consultation when she 
is older. 
P13. Association studies of SEMA6A, SEMA6B, PLXNA2 and 
PLXNA4 genes in an Irish schizophrenia case-control sample.
Elaine  Kenny1,  Derek W.  Morris1, William  P.  Gilks1,  Emma  H. 
Allott1, Gary Donohoe1, John L. Waddington2, Kevin J. Mitchell3, 
Michael Gill1, Aiden P. Corvin1.  
1  Neuropsychiatric  Genetics  Research  Group,  IMM  and  Dept.  of 
Psychiatry, Trinity College Dublin, Ireland. 
2  Royal College of Surgeons in Ireland, Dublin, Ireland. 
3  Smurfit Institute of Genetics, Trinity College Dublin, Ireland.
Schizophrenia  has  a  substantial  genetic  component.  Finding 
genetic variants that alter risk may help in identifying pathways 
that are aetiologically important, both in predicting illness risk and 
developing treatments. Work by our group and collaborators have 
identified the Semaphorin 6 and Plexin A gene families as putative 
susceptibility genes for schizophrenia. Here we report analyses of 
SEMA6A, PLXNA2, SEMA6B and PLXNA4. 
SNP maps were generated for all four genes. SNPs located within 
the gene region were ranked according to their location. Priority was 
given to SNPs in coding regions, UTR’s, splice junctions, promoter 
regions, evolutionary conserved regions, regions containing clusters 
of transcription factor binding sites (TFBS) and conserved TFBS. 
Tag SNPs were chosen using HapMap CEU linkage disequilibrium 
data. Altogether 74 SNPs were genotyped across the four loci in a 
sample of 375 schizophrenia cases and 812 controls. 
Three SNPs at SEMA6A, two SNPs at SEMA6B and three SNPs 
at PLXNA2 reached nominal levels of significance (p=0.01-0.05) 
prior to correction for multiple testing. 
Given the limited power of our association sample and the number 
of  SNPs  tested,  these  findings  require  independent  replication. 
However, the results may point to a role for abnormal axon guidance 
and cell migration in schizophrenia pathophysiology.  
P14. Absence of linkage to known loci in an Irish RLS family
Skehan EB, Abdulrahim M,  Parfrey NP, Hand CK. 
Department of Pathology, University College Cork, Ireland. 
Restless  legs  syndrome  (RLS)  is  a  neurological  sleep  disorder 
characterised by abnormal sensations in the legs associated with 
an irresistible urge to move. Symptoms occur predominantly at rest 
and worsen at night, resulting in nocturnal insomnia and chronic 
sleep deprivation. 
RLS has an estimated prevalence of 5 to 15% in the general population. 
Familial aggregation has been widely reported and the condition is 
predominantly an autosomal dominant disorder. Molecular genetic 
approaches have identified five loci on chromosomes 12q, 14q, 9p, 
2q, and 20p, in RLS-affected families from different populations. 
No disease-causing gene has yet been identified. The increase in 
symptom intensity at night has implicated the circadian system and 
response to treatment with dopamine agonists has suggested an 
abnormality in the dopaminergic pathway. 
An Irish family with autosomal dominant RLS has been recruited, 
with the aim to localise and identify the gene responsible for the 
syndrome. The five described RLS loci were examined for linkage; 
however results indicate that the new Irish RLS pedigree is not 
linked to the currently described genetic loci. This provides further 
evidence of genetic heterogeneity in RLS. Future work includes 
a genome-wide scan to identify the novel locus in this Irish RLS 
family.
P15.  The  CHEK2*1100delC  variant:  present  in  the  west  of 
Ireland breast cancer population.
Colleran G, Rowan A, Miller N, Sawyer E, Curran C, Kerin M, 
Tomlinson I.  
National University of Ireland, Galway, Ireland; Molecular and Population 
Genetics, Cancer Research UK, London, England.
Background: As part of a population-based approach to breast 
cancer genetics, a West of Ireland cohort is under study to elucidate 
inherited variation which predisposes women to developing breast 
cancer.  CHEK2  has  been  identified  as  a  low-penetrance  breast 
cancer susceptibility gene conferring a 2-fold elevated risk of breast 
cancer in women and 10-fold in men.
Materials  and  Methods:  To  evaluate  the  prevalence  of  the 
CHEK2*1100delC  variant,  DNA  collected  from  591  breast 
cancer  cases  and  572  healthy  controls  were  analysed.  FAM 
(carboxyfluorescein)  labelled  PCR  products  were  capillary 
separated on the ABI 3700 and fragment analysis carried out using 
Genotyper v2.5. Normal PCR fragments measures 168bp and the 
CHEK2*1100delC could be clearly seen at 167bp. A sequenced 
control  CHEK2*1100delC  patient  DNA  was  PCR  amplified  for 
each test reaction.
Results:  The  CHEK2  *1100delC  mutation  was  found  in  three 
cases, one had a sibling who was affected with colorectal cancer. 
The mutation was not found in any control samples. 
Discussion:  We  have  established  that  the  CHEK2*1100  delC 
variant is present in the Irish population and is in excess in cases 
over controls. Our data are consistent with effect on risk.  Its role in 
the clinical setting has yet to be elucidated.© The Ulster Medical Society, 2008.
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P16.  Genetic  interaction  assessment  of  major  Age  Related 
Macular  Degeneration  (AMD)  susceptibility  loci  within  the 
Northern Ireland population.
GJ McKay1, G Silvestri1, N Orr2, U Chakravarthy1, AE Hughes2.    
1  Centre for Vision Science and 
2  Department of Medical Genetics, Queens University Belfast, Belfast, 
United Kingdom. 
Purpose: To  assess  the  effect  of  Complement  factor  H  (CFH), 
Factor B (FB), Component C2 (C2), LOC387715/HTRA1 locus and 
the influence of Vascular Endothelial Growth Factor (VEGF) and 
Apolipoprotein E (APOE) within a Northern Ireland AMD cohort.
Methods: DNA samples (n=250) with end-stage wet AMD and an 
age and sex-matched control cohort (n=250) underwent ophthalmic 
examination with detailed medical and smoking history. Haplotype 
analysis was undertaken for CFH, CFHR1, CFHR3, LOC387715, 
FB, C2, VEGF and APOE.  Haplotypic structure for each gene was 
determined from HapMap and tagged SNPs were multiplexed using 
SNaPshot technology (ABI).
Results: Results show a higher incidence of AMD risk haplotypes 
within the affected cohort with a decreasing incidence of protective 
haplotypes when compared to the controls for CFH, C2/FB and 
LOC387715. Genetic variation within C2 and FB would appear to 
be less strongly associated with the disease cohort than previously 
reported. A significant role for VEGF in relation to wet AMD has 
not been shown.
Conclusions: It would appear that CFH and LOC387715 remain 
the most strongly associated genetic factors with AMD and that 
VEGF is unlikely to have any significant involvement with disease 
manifestation within this population.
P17. C-banding analysis of a newborn with clinical features of 
Roberts syndrome
Helen  Fitzpatrick,  Sally  Ann  Lynch,  Gillian  Clarke,  Aidan 
Doherty.  
National Centre for Medical Genetics, Ireland.
Roberts  syndrome  (pseudothalidomide  syndrome)  is  a  rare 
autosomal  recessive  syndrome  which  presents  with  craniofacial 
abnormalities, limb, heart and renal defects.  The condition has 
recently been mapped to 8p12, with mutations found in ESCO2, 
a gene essential for the establishment of sister chromatid cohesion 
responsible for clinical presentation (Vega et al., 2005).  A majority 
of  affected  individuals  (about  80%)  exhibit  a  chromosomal 
phenomenon known as “heterochromatin repulsion” (also referred 
to as premature centromere separation).
A  newborn  female  infant  of  Polish  origin  was  referred  for 
cytogenetic investigation; her clinical features included multiple 
congenital anomalies, - hypertelorism, midline cleft lip and palate, 
severe symmetrical intra uterine growth retardation, absent radii 
and talipes.
Chromosome  analysis  revealed  a  female  karyotype  of  46,XX 
chromosomes.  Approximately 50% of the cells examined exhibited 
a  characteristic  morphology  with  lack  of  a  defined  centromeric 
constriction with some pericentromeric regions being splayed out 
and appearing as “puffing”. This phenomenon is characteristic of 
Roberts syndrome.
Limb defects, cleft lip and palate, multiple congenital anomalies; 
together  with  the  characteristic  heterochromatic  repulsion  are 
diagnostic of Roberts syndrome in this patient.
P18. Tuberous Sclerosis Complex – an audit of referrals to the 
Northern Ireland Genetic Service over a four period.
Crawford H, Shepherd CW, McKee S, Morrison PJ. 
The Northern Ireland Tuberous Sclerosis Clinic, Northern Ireland Regional 
Genetics Centre, Belfast Health and Social Care Trust, A Floor, Belfast City 
Hospital, Lisburn Road, Belfast BT9 7AB
In  the  four  years  1  June  2003  –1  June  2007,  19  patients  were 
referred to the Northern Ireland Genetic Service for investigation 
of Tuberous Sclerosis Complex (TSC).
Results: 13 patients have a clinically confirmed diagnosis of TSC. Of 
these, 7 patients had seizures age <12 months as a first presentation 
of TSC. In these patients, 2 undiagnosed parents were identified as 
being TSC affected following the diagnosis in their child. 3 patients 
(age range 9 – 17) presented with angiofibromata and a diagnosis 
of TSC was made following referral by the Dermatologist. 1 TSC 
affected adult had a previously confirmed diagnosis of TSC. This 
patient came to Northern Ireland from Portugal.
Conclusion: In a stable population, the majority of patients with 
TSC are diagnosed in infancy or early childhood. A second group 
of previously undiagnosed, mildly affected adults was identified, 
following the diagnosis of TSC in their child. A third group of older 
children and adolescents was identified. An emerging trend is seen, 
where a proportion of new referrals for TSC are patients who have 
come to Northern Ireland from other parts of Europe.
P19. Audit Of Myelodysplastic Syndrome Cases Submitted For 
Cytogenetic Analysis Over A Two Year Period.
Johanna Kelly1, Eibhlin Conneally2, Elizabeth Vandenburgh2, Sally 
Ann Lynch1.   
1  National Centre for Medical Genetics, Our Lady’s Children’s Hospital, 
Crumlin, Dublin 12;
2  St James’s Hospital, Dublin 8.
Background:  Myelodysplastic  Syndromes  (MDS)  are  a  group 
of  conditions  of  progressive  bone  marrow  failure  of  normal 
maturation leading to peripheral cytopenias.  More than one cell 
lineage is involved, with often up to three.  It is typically a disease 
of the elderly.   There is a 20-40% risk of transformation from MDS 
to Acute Myeloid Leukaemia (AML). Chromosome abnormalities 
would be expected in 40-50% of MDS cases.  Evidence suggests 
that cytogenetic analysis can influence the clinical evaluation.  The 
clinical boundaries between MDS and AML are indistinct and a 
similar  overlap  occurs  cytogenetically.    Cytogenetic  analysis, 
therefore, does not prove informative for a differential diagnosis.
Aim: To minimise the number of borderline MDS cases submitted 
for cytogenetic analysis with a view to improve efficiency. This 
should allow the department to broaden the range of tests offered.
Results: 805 MDS samples were received over a two year period 
ranging from age 30-90. 164 of these samples were deemed not 
required on review of Bone Marrow morphology.  Of the remaining 
641  samples  83  of  these  samples  had  an  abnormal  cytogenetic 
karyotype.  This gives a 12.9% abnormality rate for MDS cases 
referred to this facility.  80% of the abnormal karyotype cases were 
aged between 60 and 90.
Discussion: As the expected abnormality range in a cytogenetic © The Ulster Medical Society, 2008.
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laboratory for MDS is 40-50% it is clear that a more stringent 
selection criteria needs to be implemented.  It is also evident from 
the high percentage of abnormal karyotype cases in the age range 
60-90 that MDS is a disease of the elderly.  It is proposed that 
cytogenetic analysis for all MDS cases should only be completed on 
receipt of a diagnostic bone marrow morphology report, a complete 
clinical history or by personal communication with the requesting 
consultant. 
P20.  Detection  of  subtelomeric  rearrangements  in  children 
with unexplained mental retardation using Multiplex Ligation-
dependent Probe Amplification.
Karen Meaney1, David E. Barton1. 
1  National Centre for Medical Genetics, Our Lady’s Children’s Hospital, 
Crumlin, Dublin 12.
Mental retardation is a common lifelong disability affecting 1-3% of 
the general population. The cause of the disorder remains unknown 
in approximately half of all cases which can be a source of anxiety 
for the family of the affected patient. It has been reported that 
submicroscopic subtelomeric rearrangements may be responsible 
for 2.5-10% of all unexplained mental retardation cases. 
Multiplex Ligation-dependent Probe Amplification (MLPA) can be 
used to detect cryptic subtelomeric imbalances. It has the advantage 
of being a cost effective, rapid and easy to use technique. We will 
present the results of 200 retrospective DNA samples tested for the 
presence of subtelomeric rearrangements using two different MLPA 
probe mixes. These samples are from children with unexplained 
mental retardation/developmental delay and normal karyotype and 
Fragile X results.
The objectives are to assess whether the introduction of a service in 
our laboratory to screen patients with idiopathic mental retardation/
developmental delay for subtelomeric aberrations is practicable and 
of benefit to the Irish population and to determine whether MLPA is 
a suitable technique for the detection of these anomalies. 
P21. There  is  no  evidence  of  linkage  or  association  between 
Parathyroid  Hormone  Receptor  Type  1  polymorphisms  or 
haplotypes  with  low  bone  mineral  density  in  a  Caucasian 
cohort
KG Hegarty1,2, M Daly1, F Shanahan1, MG Molloy1.
1  Deptartment of Rheumatology and Sports Medicine, National University 
of Ireland, Cork, Ireland.  
2  Department  of  Medicine,  National  University  of  Ireland,  Cork, 
Ireland.  
3  Alimentary Pharmabiotic Center, National University of Ireland, Cork, 
Ireland.
Previous  studies  have  observed  suggestive  evidence  of  linkage 
between  low  bone  mineral  density  (BMD)  and  the  parathyroid 
hormone  receptor  type  1  (PTHR1)  locus  (3p22-21.1).    In  the 
present study, we tested for association between genetic variants in 
the PTHR1 gene and variation in BMD.  
Four single nucleotide polymorphisms (SNPs), located throughout 
the PTHR1 gene, were tested for association with BMD in 278 
nuclear  families  and  500  unrelated  postmenopausal  Caucasian 
women.
There was no evidence of linkage between the PTHR1 genotypes 
and BMD using Merlin (LOD scores < 1.0).  The Family Based 
Association Test (FBAT) was used to test for association between 
the  PTHR1  genotypes  and  haplotypes  with  BMD.    There  was 
significant association between SNP rs4683301 with variation in 
BMD at the femoral neck (P = 0.03) and lumbar spine (P = 0.02) 
using the genotype model in FBAT.  However, following adjustment 
for covariates, there was no significant association (P >0.05). The 
PTHR1 haplotype, h3 (TC), was significantly associated with BMD 
at both skeletal sites (P < 0.00).  However, after correction for 
covariates, there was no significant association.
Denser  SNP  genotyping  may  be  necessary  to  better  define  the 
possible relationship between the PTHR1 gene and BMD variation 
in this cohort.
P22.  Association  of  Methylenetetrahydrofolate  reductase 
(MTHFR)  polymorphism  and  the  risk  of  Squamous  Cell 
Carcinoma in renal transplant patients. 
Mary E Laing1, Patrick Dicker2, Wen Lyn Ho1, Fergal J Moloney1, 
Gillian M Murphy1, Peter Conlon3, Alexander S Whitehead4, Denis 
C Shields5  
1.  Department of Dermatology, Beaumont Hospital, Dublin 9.  
2.  Department of Molecular and Cellular Therapeutics, Royal College of 
Surgeons in Ireland. 
3.  Department of Nephrology, Beaumont Hospital, Dublin 9.  
4.  Department  of  Pharmacology  and  Center  for  Pharmacogenetics, 
University of Pennsylvania 
 School of Medicine, Pennsylvania, USA 5UCD Conway Institute 
of  Biomolecular  and  Biomedical  Research,  University  College 
Dublin, Dublin 4, Ireland
Background: The relative risk of developing cutaneous squamous 
cell carcinoma (SCC) is significantly increased following organ 
transplantation. 
Objective:  We  investigated  genetic  association  with  SCC  in 
two  pathways  associated  with  cancer  risks,  with  potential  for 
modification by vitamin supplementation. 
Methods: 367 renal transplant recipients (117 with SCC and 250 
without any skin cancer) were genotyped for key polymorphisms in 
the folate pathway (MTHFR: C677T; methylene tetrahydrofolate 
reductase), and the vitamin D pathway (VDR: Intron 8 G/T; vitamin 
D receptor). 
Results:  Individuals  carrying  the  MTHFR  677T  allele  had  a 
marked  increase  in  risk  of  SCC  (adjusted  OR=  2.54,  p=0.002, 
after adjustment for age, sex, skin type, sun exposure score and 
immunosuppression duration; lower 95% confidence boundary OR 
of 1.41). In contrast, VDR polymorphisms were not significantly 
associated.  
Conclusion: Folate-sensitive pathways may play a critical role in 
the elevated rate of SCC in renal transplant recipients.  
P23. Study of the Knowledge of Inherited Metabolic Disorders 
among patients and their families in the Irish population
Rosie O’Shea1, Eileen Treacy2, Anne Marie Murphy2, Sally Ann 
Lynch3, Deborah Lambert2,3. 
1  Department of Medical Genetics Cardiff University, 
2  The  National  Centre  for  Inherited  Metabolic  Disorders,  Children’s 
University Hospital, Temple Street, 
3   National Centre for Medical Genetics, Dublin.© The Ulster Medical Society, 2008.
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Galactosaemia  and  Maple  Syrup  Urine  Disease  (MSUD)  are 
recessively inherited conditions screened for by newborn screening 
in Ireland. Affected patients are followed at the National Centre 
for Inherited Metabolic Disease. We aimed to assess the degree 
of genetic knowledge imparted to families to determine if further 
formal genetic counselling would be beneficial. Adult patients and 
parents of affected children were interviewed in person using a 
questionnaire including 4 demographic, 8 knowledge, 2 information 
and  5  impact  questions.  To  date,  8  adults  (7  galactosaemia,  1 
MSUD) and 18 parents (12 galactosaemia and 6 MSUD) have been 
interviewed. All parents of children with MSUD correctly answered 
questions on MSUD and recurrence, but did not know the risk or 
implications of carrier status. For galactosaemia; 9 of 12 parents 
scored 6/8 or better on knowledge, while all adults scored 3 to 5 
of 8. 16/26 study participants requested more information about 
their condition and its transmission. Affected adults also identified 
a need to meet others with the same condition. Our study to date 
indicates that parents of children with these genetic disorders are 
well informed, however adult patients could benefit from further 
genetic  counselling.  This  may  reflect  a  reluctance  to  transmit 
genetic information within families.
P24. Determination of the most stable endogenous control gene 
using an in vitro model of folate deficiency.
Carroll N1,2, Cahill S1, O’Brien K 1Scott JM2, & Parle-McDermott 
A1.  
1   Nutritional Genomics Research Group, School of Biotechnology, Dublin 
City University, Ireland 
2   School  of  Biochemistry  &  Immunology,  Trinity  College  Dublin, 
Ireland. 
Folate is an essential nutrient necessary for DNA synthesis, cellular 
proliferation  and  biological  methylation  reactions.  Suboptimal 
folate  status  is  a  risk  factor  for  several  human  diseases.  An 
understanding of the molecular mechanisms linking folate status to 
these conditions is still incomplete. In a bid to dissect the molecular 
response  to  folate  status  we  set  up  an  in  vitro  model  of  folate 
depletion. RT-PCR is currently the method of choice to examine 
expression levels of a specific set of genes. Key to this method 
is normalisation of results to an appropriate endogenous control 
gene that is relatively unaffected by the experimental conditions. 
Inaccurate normalization can lead to findings that do not reflect 
the true experimental variation. We sought to identify the most 
appropriate  endogenous  control  gene  for  normalisation  of  gene 
expression data in our in vitro model of folate depletion in HEK293 
cells to ensure only true gene-specific variation in response to folate 
levels will be reported. This was undertaken using the TaqMan® 
Human Endogenous Control Plate that enables the evaluation of 11 
endogenous control genes. HEK293 cells were cultured for 14 days 
in conditions of depleting folate. Decline in cellular folate levels was 
confirmed by intracellular folate assay. Duplicate cDNA samples 
from Day0, 3, 8 and 14, representing different degrees of folate 
depletion, were used. RT-PCR was performed on an ABI 7500 PCR 
System. GUS control gene was shown to be the endogenous control 
gene that displayed the least amount of variation across samples and 
therefore is the most accurate choice as a single normalisation gene 
for HEK-293 cells under conditions of depleting folate. 
P25. Down syndrome and Achondroplasia: A rare combination
Tabib  Dabir1,  Brian  McCrossan2, A  Sands2,  L  Sweeney3  and A 
Magee1   
1  Northern Ireland regional genetics Service, Belfast City Hospital, Belfast 
BT9 7AB, 
2  Department of Paediatric Cardiology, 
3  Department of Paediatric Radiology, Royal Belfast Hospital for Sick 
Children, Belfast, BT12 6BA tabib.dabir@belfasttrust.hscni.net
Achondroplasia and Down syndrome are the commonest genetic 
conditions within their respective categories.  Presence of these two 
genetic entities in the same patient is a rare event and has been 
reported only thrice in medical literature.  We report the fourth case 
with this rare combination. 
The proband was a female infant born at term to a Caucasian couple 
with maternal and paternal age of 41 and 43 years respectively. The 
clinical features included frontal bossing, flat nasal bridge, down 
slanting palpebral fissures, long philtrum, thin lips and bilateral 
simian  creases  and  Tetralogy  of  Fallot.  The  clinical  diagnosis 
of Down syndrome was confirmed by karyotyping. She also had 
relatively large head, depressed nasal bridge, rhizomelic shortening 
of all limbs, protuberant abdomen and trident configuration of both 
hands. These features were suggestive of achondroplasia and the 
radiological features were consistent with this diagnostic possibility.   
FGFR3 gene mutation analysis showed G380R G > A mutation. 
The combination of Down syndrome and achondroplasia in our 
patient  is  likely  to  be  a  chance  event  because  of  the  advanced 
parental ages.  Molecular confirmation of achondroplasia is not 
routinely requested.  However it was extremely useful in this case 
from diagnosis and counselling point of view.  
P26. Natural history of Williams Syndrome: a report of 2 cases  
Tabib Dabir1, Alex Magee1 , Alistair N Graham2   
1  Northern  Ireland Regional Genetics Service, Belfast City Hospital, 
Lisburn Road, Belfast BT9 7AB, 
2  Department of Cardiothoracic Surgery, Royal Hospitals, Grosvenor Rd, 
Belfast BT12 6BA. tabib.dabir@belfasttrust.hscni.net
Williams syndrome (WS) is a well described genetic syndrome 
affecting 1 in 20,000.  However there is relative paucity of medical 
literature devoted to adults with this condition.  We report 2 adults 
with WS diagnosed in their late 50s.
Case  1:  57  year  old  lady  referred  with  clinical  suspicion  of 
Turner  syndrome.    She  has  learning  difficulties,  short  stature, 
kyphoscoliosis,  joint  stiffness,  cardiac  pacemaker  for  complete 
heart  block,  abnormal  glucose  tolerance  test,  hypertension  and 
constipation.  She lives in a residential home with her older sister 
who also has learning difficulties and short stature.
Case 2: 57 year old man referred to genetics department with clinical 
features, mild learning difficulties, diabetes, sensorineural hearing 
loss, constipation, and was operated for inguinal hernia, bladder 
diverticulae, aortic valve replacement and aneurysm of ascending 
aorta.  He also had stroke and has never lived independently.
These are probably the oldest reported cases of WS.  Their clinical 
features  and  the  associated  medical  complications  delineate  the 
natural history of this condition.  It also highlights the need for better 
understanding/  awareness  of  this  condition  among  professionals 
working in adult services. 
P27. Implementation of a Luminex-based CF Assay at NCMG – 
A Validation Experience
Trudi McDevitt, Caitriona King,  Melissa Rogers, Solvig Roring, 
Shirley McQuaid, David E Barton. 
National  Centre  for  Medical  Genetics,  Our  Lady’s  Children’s  Hospital, 
Dublin, Ireland. Email: trudi.mcdevitt@olhsc.ie© The Ulster Medical Society, 2008.
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With  the  aim  of  improving  the  efficiency  of  the  NCMG  cystic 
fibrosis (CF) service, we looked for a multiplexed CF assay which 
could be adapted to the mutation spectrum of the Irish population. 
Using Luminex™ Liquid Bead Array Platform (Applied Cytometry), 
we evaluated the Signature CF 2.0 ASR from Asuragen which 
tests for 25 of the CF mutations included in the ACMG/ACOG 
recommended CF panel.
We evaluated this assay on a variety of sample types and on a 
large  cohort  (n=468)  of  DNA  samples  of  known  genotypes  to 
examine sensitivity and specificity.  All samples except one were 
genotyped correctly during this initial validation, indicating that the 
Signature CF 2.0 ASR was a sensitive and robust assay for CF 
diagnostics. We observed a discordant result between our ARMS 
assay and the Signature CF 2.0 ASR for one sample.  Subsequent 
investigations revealed this discrepancy to be due to the presence 
of CF mutation V520F, which resulted in non-amplification of the 
mutant allele due to its position under the exon 10 forward primer 
in the Signature CF 2.0 ASR.   
We  describe  collaborative  efforts  by  NCMG  and  Asuragen  to 
address the issue of SNPs under primers in commercial ASRs.
P28.  Partial  trisomy  13:  A  case  report,  verification  of  the 
phenotype and review of the literature
G Smith, D McManus, V McConnell.  
NI. Regional Genetics Service, Belfast City Hospital, Belfast Health and 
Social Care Trust
Partial  trisomy  for  distal  chromosome13  has  previously  been 
described  in  20  patients.  The  reported  phenotype  consists  of 
microcephaly,  distinctive  facies,  high  arched  palate,  postaxial 
polydactyly, genitourinary anomalies, 2/3 toe syndactyly, moderate 
mental retardation and relatively few major malformations. 
We describe a further case in a male infant born by emergency C/S 
to a primagravida due to failed induction at T+3, after an uneventful 
antenatal history. Birth weight was on 75th centile. On examination 
he  presented  with  striking  dysmorphic  features,  a  high  arched 
palate, long fingers and toes with bilateral postaxial polydactyly, 
bilateral 2/3 soft tissue toe syndactyly and hypospadias. 
Cytogenetic analysis revealed additional chromosome material at 
9p24.1 which was confirmed as 13q22.3->qter by FISH studies. 
Subsequent  parental  chromosome  analysis  indicated  that  the 
unbalanced rearrangement had arisen from an adjacent I segregation 
of a maternal t(9;13)(p24.1;q22.3). 
This  case  provides  further  evidence  that  trisomy  13q22.3->qter 
presents with a characteristic spectrum of abnormalities. A review 
of the literature indicates that, of the features of full trisomy 13, 
congenital heart defects, clinodactyly and frontal bossing appear 
to be associated with proximal 13q trisomy, while genitourinary 
anomalies, micropthalmia, cleft palate and polydactyly are more 
prevalent in trisomy for distal 13q.
P29. A Genotype-Phenotype Correlation Study In An Extended 
Irish  Kindred With Variegate  Porphyria  Caused  By    PPOX 
Q435X 
1VEF  Crowley,  1K  Lim,  1C  Darby,  1C  Collison,  1A  Balfe,  2S 
Heggarty  
1.   Biochemistry Department, Central Pathology Laboratory, St James’s 
Hospital, Dublin 8. 
2.   Genomics  Core  Facility,  Regional  Genetics  Centre,  Belfast  City 
Hospital
Variegate  porphyria  (VP)  is  genetically  heterogeneous,  and 
demonstrates  variable  penetrance  and  expressivity  of  clinical 
and biochemical phenotype within affected families. Phenotypic 
variability may be related to the nature of the underlying pathogenic 
mutation.  Q435X  is  the  most  common  VP-causing  mutation 
encountered in the UK (7%) and we report a genotype-phenotype 
correlation study of Q435X in an extended Irish kindred  
Molecular genetic scanning of PPOX identified a nonsense mutation 
Q435X in two subjects with confirmed VP. A further twenty-two 
adult members of this extended family were screened for Q435X. In 
total 67% (16 out of 22) were mutation positive.  Plasma fluorescent 
emission  spectroscopy  (PFS)  screening  was  also  undertaken  in 
all subjects, and had a specificity of 100% but sensitivity of only 
80%.  A clinical questionnaire revealed that only 19% (3 out of 
16) of mutation positive subjects had clinically overt cutaneous 
manifestations of VP and13% (2 out of 16) had experienced acute 
episodes. 
The results of this  genotype-phenotype study suggests that Q435X 
demonstrates  a  less  penetrant  cutaneous  phenotype  but  greater 
penetrance of acute neurovisceral attacks than a well characterised 
South African founder mutation R59W. Furthermore, PFS was only 
80% sensitive, thus confirming that mutation analysis is diagnostically 
superior in the detection of presymptomatic carrier status. 
P30. The Molecular Basis of Acute Porphyria in the Republic 
of Ireland.
1Vivion EF Crowley, 1Cindy Darby, 2S Heggarty, 3Sharon Whatley, 
3Mike Badminton.  
1.   Biochemistry Department, Central Pathology Laboratory, St James’s 
Hospital, Dublin 8,  
2.  Genomics  Core  Facility,  Regional  Genetics  Centre,  Belfast  City 
Hospital. 
3.   Cardiff  Porphyria  Centre,  Department  of  Medical  Biochemistry, 
University Hospital of Wales, Heath Park, Cardiff
Acute  porphyrias,  which  include  acute  intermittent  porphyria 
(AIP),  variegate  porphyria  (VP)  and  hereditary  coproporphyria 
(HP),  are  autosomal  dominantly  inherited  disorders  affecting 
key enzymes in the haem biosynthetic pathway, and demonstrate 
variable  penetrance  (20%)  and  expressivity.  Clinically  these 
disorders may manifest with photosensitive skin lesions (VP and 
HP) and/or acute neurovisceral episodes (AIP, VP and HP), the 
latter being potentially associated with significant morbidity. While 
biochemical  investigations,  including  blood,  urine  and  faecal 
porphyrin analysis, are critical for the diagnosis of active porphyric 
disease, these investigations may not be sensitive enough to identify 
presymptomatic  mutation  carriers.  Hence  molecular  genetic 
analysis has become an important component in kindred follow-up 
for identifying porphyria susceptibility. 
The  Biochemistry  Department,  St  James’s  Hospital,  Dublin, 
in  collaboration  with  Cardiff  Porphyria  Centre,  have  recently 
established a biochemical genetic service for the acute porphyrias. 
Mutation scanning using PCR and direct nucleotide sequencing has 
identified 11 different mutations in 12 porphyria kindred within 
the Republic of Ireland. This includes mutations in HMBS (R26C, 
R26H,  IVS4+1G>A),  PPOX  (IVS4-1G>A,  Q435X,  W427X, 
A150D, Q375X) and CPO ( R332Q, R332W, c.1291-1292 ins TG), 
causing AIP, VP and HP respectively. © The Ulster Medical Society, 2008.
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This unique insight into the molecular basis of porphyria in the ROI 
population clearly indicates that acute porphyrias are genetically 
heterogenous within this cohort. 
P31. Genetic variants of Complement factor H gene are not 
associated with premature coronary heart disease: a family-
based study in the Irish population
Meng W1, Hughes A1, Patterson CC 1, Belton C1, Kamaruddin MS2, 
Horan PG2, Kee F1, McKeown PP1,2.  
1.   Centre for Clinical and Population Sciences, Queen’s University Belfast, 
Institute  of  Clinical  Science,  Grosvenor  Road,  Belfast,  BT12  6BJ, 
Northern Ireland, UK. 
2.   Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor 
Road, Belfast, BT12 6BA, Northern Ireland, UK. 
Background:  The  complement  factor  H  (CFH)  gene  has  been 
recently confirmed to play an essential role in the development of 
age-related  macular  degeneration  (AMD). There  are  conflicting 
reports  of  its  role  in  coronary  heart  disease.  This  study  was 
designed to investigate if, using a family-based approach, there was 
an association between genetic variants of the CFH gene and risk of 
early-onset coronary heart disease.
Methods: We evaluated 6 SNPs and 5 common haplotypes in the 
CFH gene amongst 1494 individuals in 580 Irish families with at 
least one member prematurely affected with coronary heart disease. 
Genotypes were determined by multiplex SNaPshot technology.
Results: Using the TDT/S-TDT test, we did not find an association 
between any of the individual SNPs or any of the 5 haplotypes and 
early-onset coronary heart disease. 
Conclusion: In this family-based study, we found no association 
between the CFH gene and early-onset coronary heart disease. 
P32. Identifying potential candidate genes in an Irish bipolar 
disorder sample linked to 14q21-32.
Cassidy F, Zhao C, Badger J, Delaney C, Mooney L, Roche S, 
McKeon P, Dobrin SE.  
Trinity College Dublin, Dublin, Ireland.
Bipolar  affective  disorder  (BPAD)  is  a  severe  and  debilitating 
psychiatric illness. Family, twin and adoption studies have established 
a substantial genetic component to the illness but the genes involved 
have yet to be fully elucidated. A 10cM genome-wide linkage scan 
(WGS) was performed in a collection of 60 Irish BPAD affected sib 
pairs to locate chromosomal regions that may harbour susceptibility 
genes. The most significant result was on chromosome 14 at 75cM 
(14q24). Since the region of the chromosome containing significant 
P values was substantial, we undertook a fine-mapping analysis 
to refine the linkage peak. 144 SNP markers (400kb resolution) 
were analysed in an extended sample of 88 ASPs. Linkage analysis 
resolved our original linkage peak into 4 separate peaks, two of 
which overlap with published linkage peaks for related psychiatric 
disorders, such as anxiety and alcoholism. The most significant 
NPL score of 2.71 was at 67.84Mb, remarkably close to the original 
WGS peak score at 68.2Mb. In an additional analysis, two SNPs 
were found to be associated with BPAD (rs24166076 at 46.97Mb 
and rs4902942 at 71.21Mb). This project has substantially refined 
the  region  of  chromosome  14  predicted  to  contain  a  candidate 
susceptibility gene for BPAD.
P33. Estimating carrier risks by linkage in a Duchenne Muscular 
Dystrophy family with a triple X female 
Aileen Butler, David E Barton. 
National  Centre  for  Medical  Genetics.  Our  Lady’s  Childrens’  Hospital, 
Crumlin, Dublin 12.
We received a referral for carrier status on a female with a brother 
deceased with a clinical diagnosis of DMD, and no genetic testing 
done.  There was no other family history of DMD.  The consultand’s 
mother had a CK of 480, and a number of other children (2 daughters 
and 1 unaffected son), all of whom had different fathers.  The two 
eldest daughters had been adopted separately at an early age, and 
were also requesting information regarding carrier status.  DNA 
samples from their fathers were unavailable, but we did receive a 
sample from their unaffected half-brother.  Thus, the request was 
for linkage analysis in a very unusual and complicated pedigree, 
where  samples  were  unavailable  from  many  significant  family 
members, including the index case.  Linkage analysis commenced, 
yielding unexpected results which provided evidence of 3 distinct 
alleles at 5’, intergenic, and 3’ Dystrophin polymorphic markers in 
the index case’s mother.  Subsequent cytogenetic analysis confirmed 
a 47, XXX karyotype.  Despite the presence of three Dystrophin 
haplotypes in her, and the complex pedigree, we were successful 
in haplotyping the family.  Furthermore, it was possible to assign 
carrier risks to all at-risk females, two of whom were estimated to 
be at a <1% risk. 
P34. Distal Duplication 10q: a case of gonadal mosaicism?
David McManus, June Jones, Moya Clarkson, Alex Magee
Regional  Genetics  Service,  Belfast  City  Hospital,  Belfast  BT9 
7AB.
Partial duplication of chromosome 10q is a rare abnormality usually 
associated with significant dysmorphism and intellectual deficit. 
The majority of published reports relate to segments encompassing 
up to one third of the long arm. Typically another chromosome is 
involved, which is likely to influence the phenotype. We present two 
sibs with a pure duplication of the most distal bands of chromosome 
10q who show a relatively mild phenotype. TM and EM are sisters, 
in a sibship of five, who present with developmental delay but no 
significant dysmorphic features. Cytogenetic analysis demonstrated 
a small distal duplication comprising bands 10q26.13 to 10q26.3. 
Parental karyotypes were normal, suggesting gonadal mosaicism. 
Phenotypic expression is more developed in TM, the elder sister, 
who is now 10 years old. She presents with learning and behavioural 
difficulties with minor stereotypic movements, low muscle tone, 
hyperextensible joints, slight bilateral clinodactyly and exaggerated 
lumbar lordosis. The mild phenotype is clearly a function of the 
small size of 10q duplication in contrast to the severe phenotype 
normally observed.